PMID- 23478318
OWN - NLM
STAT- MEDLINE
DCOM- 20130617
LR  - 20211021
IS  - 1098-5522 (Electronic)
IS  - 0019-9567 (Print)
IS  - 0019-9567 (Linking)
VI  - 81
IP  - 5
DP  - 2013 May
TI  - Vaccination with the recombinant major outer membrane protein elicits antibodies 
      to the constant domains and induces cross-serovar protection against intranasal 
      challenge with Chlamydia trachomatis.
PG  - 1741-50
LID - 10.1128/IAI.00734-12 [doi]
AB  - To determine the ability of the major outer membrane protein (MOMP) to elicit 
      cross-serovar protection, groups of mice were immunized by the intramuscular 
      (i.m.) and subcutaneous (s.c.) routes with recombinant MOMP (rMOMP) from 
      Chlamydia trachomatis serovars D (UW-3/Cx), E (Bour), or F (IC-Cal-3) or 
      Chlamydia muridarum strain Nigg II using CpG-1826 and Montanide ISA 720 VG as 
      adjuvants. Negative-control groups were immunized i.m. and s.c. with Neisseria 
      gonorrhoeae recombinant porin B (Ng-rPorB) or i.n. with Eagle's minimal essential 
      medium (MEM-0). Following vaccination, the mice developed antibodies not only 
      against the homologous serovar but also against heterologous serovars. The 
      rMOMP-vaccinated animals also mounted cell-mediated immune responses as assessed 
      by a lymphoproliferative assay. Four weeks after the last immunization, mice were 
      challenged i.n. with 10(4) inclusion-forming units (IFU) of C. muridarum. The 
      mice were weighed for 10 days and euthanized, and the number of IFU in their 
      lungs was determined. At 10 days postinfection (p.i.), mice immunized with the 
      rMOMP of C. muridarum or C. trachomatis D, E, or F had lost 4%, 6%, 8%, and 8% of 
      their initial body weight, respectively, significantly different from the 
      negative-control groups (Ng-rPorB, 13%; MEM-0, 19%; P < 0.05). The median number 
      of IFU recovered from the lungs of mice immunized with C. muridarum rMOMP was 
      0.13 x 10(6). The median number of IFU recovered from mice immunized with rMOMP 
      from serovars D, E, and F were 0.38 x 10(6), 7.56 x 10(6), and 11.94 x 10(6) IFU, 
      respectively. All the rMOMP-immunized animals had significantly less IFU than the 
      Ng-rPorB (40 x 10(6))- or MEM-0 (70 x 10(6))-immunized mice (P < 0.05). In 
      conclusion, vaccination with rMOMP can elicit protection against homologous and 
      heterologous Chlamydia serovars.
FAU - Tifrea, Delia F
AU  - Tifrea DF
AD  - Department of Pathology and Laboratory Medicine, Medical Sciences I, University 
      of California, Irvine, Irvine, California, USA.
FAU - Ralli-Jain, Pooja
AU  - Ralli-Jain P
FAU - Pal, Sukumar
AU  - Pal S
FAU - de la Maza, Luis M
AU  - de la Maza LM
LA  - eng
GR  - R01 AI067888/AI/NIAID NIH HHS/United States
GR  - R01 AI092129/AI/NIAID NIH HHS/United States
GR  - AI-67888/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20130311
PL  - United States
TA  - Infect Immun
JT  - Infection and immunity
JID - 0246127
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Antibodies, Bacterial)
RN  - 0 (Bacterial Outer Membrane Proteins)
RN  - 0 (Bacterial Vaccines)
RN  - 0 (Recombinant Proteins)
SB  - IM
MH  - Adjuvants, Immunologic/administration & dosage/pharmacology
MH  - Administration, Intranasal
MH  - Animals
MH  - Antibodies, Bacterial/blood
MH  - Bacterial Outer Membrane Proteins/administration & dosage/*immunology
MH  - Bacterial Vaccines/administration & dosage/*immunology
MH  - Body Weight/immunology
MH  - Chlamydia Infections/immunology/*prevention & control
MH  - Chlamydia muridarum/isolation & purification
MH  - Chlamydia trachomatis/*immunology
MH  - Colony Count, Microbial
MH  - Female
MH  - Immunity, Humoral/physiology
MH  - Lung/microbiology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Recombinant Proteins/immunology
MH  - T-Lymphocytes/immunology
MH  - Vaccination/methods
PMC - PMC3648024
EDAT- 2013/03/13 06:00
MHDA- 2013/06/19 06:00
PMCR- 2013/11/01
CRDT- 2013/03/13 06:00
PHST- 2013/03/13 06:00 [entrez]
PHST- 2013/03/13 06:00 [pubmed]
PHST- 2013/06/19 06:00 [medline]
PHST- 2013/11/01 00:00 [pmc-release]
AID - IAI.00734-12 [pii]
AID - 00734-12 [pii]
AID - 10.1128/IAI.00734-12 [doi]
PST - ppublish
SO  - Infect Immun. 2013 May;81(5):1741-50. doi: 10.1128/IAI.00734-12. Epub 2013 Mar 
      11.